DDP-4 inhibitors versus sulphonylureas and cardiovascular outcomes: a meta-analysis of observational comparative studies

Abstract

INTRODUCTION: Dipeptidyl peptidase IV inhibitors (DPP4i) and sulphonylureas are commonly prescribed antidiabetic treatments, particularly after the failure of metformin monotherapy. Although DPP4i have demonstrated non-inferiority versus to placebo in clinical trials, their relative effectiveness in reducing cardiovascular events compared to sulphonylureas was evaluated in observational studies.

AIMS: To evaluate the risk of mortality (all-cause and cardiovascular) and major cardiovascular adverse events (MACE) in patients treated with DPP4i versus sulphonylureas.

Read More

Citation
Alves C, Mendes D, Batel Marques F. Presented at ATTD 2019.
Transradial_Highlights